"Zhiyi Biological" completes 300 million yuan B Series B financing

On the 4th news on the 4th, Zhiyi Bio completed a RMB 100 million B ++ round of financing. At this point, Zhiyi Bio has completed a series of financing of 300 million yuan in Series B in 18 months. It is reported that this round of funds is mainly used to accelerate the clinical development of the company's new drug pipelines.

Company information shows that Zhiyi Bio was established in 2013, and is a research and development of a Live Biotherapeutics (LBPS) and the second-generation probiotics (NGPS), based on China, is based on China and the world. Original new drug research and development enterprises in the clinical development stage. Zhiyi Bio has grown rapidly. It has become a leader in the industry. It has a complete technology and industrialization platform from the strain to LBP development. It has achieved the first LBP drug in China to enter the clinic The clinical research of tumors and other major milestones.

Zhiyi Bio's product pipelines include SK08, SK10, SK12, SK16, TP2, ZY19, etc. At present, in Zhiyi's new drug pipeline, SK08 is the fastest-growing LBP drug in China. Phase II clinical research on IBS-D (diarrhea-type intestinal syndrome) will be completed at the end of this year. SK08 combined with PD-1 suppression The clinical phase IB/II phase of advanced physical tumors has been launched. The FDA/NMPA registration of other multiple pipelines is underway. It is expected that multiple varieties will enter the clinical stage one after another next year. The smooth completion of this financing was positive for subsequent clinical trials.

Smart bud TFFI science and technology innovation assessment platform shows that Zhiyi's science and technology innovation capabilities in the biomedical industry are rated as A -level. At present, there are more than 40 patent applications, all of which are invention patents. Digestive systems and other related fields.

- END -